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underestimate the complexity of both treatment and out-
comes for those with schizophrenia.
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SCHIZOPHRENIA:A PROPENSITY SCORE
MODEL TO PREDICT SELECTION OF ATYPICAL
ANTIPSYCHOTIC
Irish W1, Neighbors D1, Grogg A2, Lopez R1, Girts T2,
Degen K3
1RTI Health Solutions, Research Triangle Park, NC, USA;
2Janssen Pharmaceutica,Titusville, NJ, USA; 3Middlesex
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OBJECTIVE: Medical records provide a potential wealth
of information about treatment effects; however, differ-
ences in pretreatment patient or other characteristics may
inﬂuence treatment assignment. This, in turn, could lead
to biased estimates of treatment effects in nonrandomized
studies. We developed a statistical model using propen-
sity scores to reduce treatment selection bias in analyses
based on retrospective data.
METHODS: As part of a study described elsewhere, we
abstracted retrospective data from the medical records of
327 patients treated for schizophrenia or schizoaffective
disorder with risperidone, olanzapine, or quetiapine at 
3 acute inpatient mental health facilities. Data were 
collected on patients from the inpatient hospitalization
through 60 days following initiation of study drug. Using
a multinomial logistic regression analysis of pretreatment
patient and other characteristics, we developed a predic-
tive model of treatment assignment to risperidone, 
olanzapine, or quetiapine.
RESULTS: The following variables were signiﬁcantly pre-
dictive of treatment assignment: age at admission, gender,
race, smoker at admission, history of substance abuse,
prior use of clozapine, and facility. The following vari-
ables were among those not signiﬁcantly predictive of
treatment assignment: prior use of atypical antipsychotics
other than clozapine, body mass index at admission, 
age at ﬁrst hospitalization for mental illness, and history
of suicide attempts, violence, glucose abnormalities, or
seizures.
CONCLUSION: The propensity score model offered a
means to adjust for treatment selection bias in a nonran-
domized study comparing treatment effects of risperi-
done, olanzapine, and quetiapine in an inpatient setting.
In addition, the propensity score methodology can be
used by researchers responsible for designing non-
randomized studies of healthcare interventions and 
decision-makers who are responsible for evaluating and
interpreting the results in this disease area.
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CARE FOR ATTENTION-
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OBJECTIVES: Although effective pharmacologic treat-
ment for attention-deﬁcit/hyperactivity disorder (ADHD)
is widely available, little is know about the quality of such
care. This is unfortunate, because the burden of inappro-
priate or inadequate treatment, in terms of increased risk
for psychiatric comorbidity, chronic decrements in func-
tioning, and higher medical costs, is borne by patients,
families, employers and healthcare systems. We therefore
sought to develop a methodology to evaluate quality of
ADHD pharmacologic care.
METHODS: Among members continuously enrolled in a
pharmacy beneﬁts management plan during the year
2000, we used claims data to identify all psychostimu-
lants ﬁlled for ADHD-related treatment during a 3-month
index period (108, 819 ﬁlls for 51, 486 patients). We next
calculated average daily dose by psychostimulant class
(methylphenidate, amphetamine salts, dextroampheta-
mine, pemoline, and methamphetamine). Based upon 
previous research, we then created a metric to convert
average daily dose across psychostimulant classes into
“Methylphenidate Equivalent Units” (MEU).
RESULTS: Average daily MEU dose was 27.3mg.
Patients averaged 2.1 ﬁlls per 3-month period, at an
average of 25.5 days supplied per ﬁll. Thus, patients typ-
ically received medication coverage throughout 51 of 
the 91-day index period (56%). This is the equivalent of
receiving medication coverage for 3.9 days per week. If
medication was, in fact, taken every day, average daily
MEU dose would be nearly halved (15.3mg).
CONCLUSIONS: We describe a methodology for evalu-
ating quality of ADHD pharmacologic care. Whether
ﬁndings suggest under-treatment requires future research
linking average daily MEU dose to targeted outcomes 
of care. Guidelines recently published by the American
Academy of Pediatrics note that ADHD treatment
requires continuous monitoring “to maximize function
across multiple domains.” By incorporating our method-
ology into large-scale prescription feedback and moni-
toring systems, the burden of inappropriate or inadequate
ADHD treatment that is borne by patients, families,
employers, and healthcare systems may be ultimately 
mitigated.
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OBJECTIVES: The Pediatric Economic Database Evalu-
ation (PEDE) Project features a database of 787 pediatric
economic evaluations published between 1980 to 1999.
Our research objective was to use the PEDE database to
examine trends in the application of health economic
methods to a pediatric population.
METHODS: Frequency distributions and cross-
tabulations were performed on the following variables:
period of publication, age group, ICD-9-CM category,
intervention, outcome and analytic technique.
RESULTS: The number of publications increased six-fold
between 1980–84 to 1995–99 from 61 to 440 citations
per 5-year period. Thirty-two percent of all studies were
published in journals for pediatrics or perinatal medicine
and 26% appeared in sub-specialty journals. Cost-
effectiveness analyses were most frequent, representing
74% of all studies. Throughout the period, the propor-
tion of cost-effectiveness analyses increased by 50%, and
decreased for cost-beneﬁt and cost-minimization analy-
ses. Although most studies were performed in children 
(1–12 years of age), this frequency decreased with time
while studies in infants became more prevalent. Most
publications were classiﬁed under the infective and para-
sitic ICD-9-CM category, comprising 24% of studies.
Health prevention studies became less frequent and health
treatment studies more predominant with time. Most
studies consisted of malaria control and vaccination
strategies for hepatitis B, Hemophilus inﬂuenzae type B,
measles, and varicella. The most common health outcome
measure was cases of abnormality, which accounted for
42% of outcomes.
CONCLUSIONS: The number of pediatric economic
evaluations is steadily increasing with most publications
representing health prevention interventions. The major-
ity of publications include cost-effectiveness analyses,
especially among children aged 1 to 12 years. Further
research is ongoing to determine how the quality of the
studies has changed over time.
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EVALUATING HEALTH PLAN MANAGEMENT OF
EMPLOYER INDIRECT COSTS:
METHODOLOGICAL ISSUES
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OBJECTIVE: Information on Managed Care Organiza-
tions’ (MCOs) performance in managing direct and 
indirect costs (absenteeism and presenteeism) allows
employers to make more informed purchasing decisions.
This paper examines challenges in evaluating MCOs’
management of indirect costs.
METHODS: The framework for evaluating MCOs com-
pares “observed” to “expected” performance in manag-
ing lost productive work time (LPT) for a speciﬁc health
condition. A credible and fair evaluation requires: i) a 
reference database deﬁning “expected” LPT for a health
condition; ii) LPT data on a random sample of the MCOs
membership who work for pay deﬁning “observed” per-
formance; iii) metrics comparing observed to expected
LPT for a speciﬁc health condition; and iv) a method 
to translate metrics into an understandable performance
score. Issues related to each component are discussed
below.
RESULTS: i) The reference must provide credible data on
expected LPT for a speciﬁc health condition that includes
missed workdays and lost productive time while at work.
Self-reported information using a validated interview in 
a representative sample of US workers is one method.
Recall period and essential data elements need to be con-
sidered. ii) Data collection should be in a representative
sample of MCO members, interviewed using the reference
population instrument. Cost/interview and prevalence of
speciﬁc health conditions will drive sample size needs. iii)
Two comparative metrics of interest include a) condition-
speciﬁc prevalence; and b) LPT/week among those with
the condition. We propose logistic regression to model
LPT (a non-normally distributed variable) and adjust 
for covariates. iv) Resulting metrics must be translated
into simple, easy-to-use, and universally understood 
terminology.
CONCLUSIONS: In operationalizing the MCO evalua-
tion process, we consider a hypothetical application using
data from the American Productivity Audit (an on-going
national survey of health-related LPT) as a reference. We
will examine the 10 health conditions with the greatest
impact on work loss.
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In this study, two available methods of item reduction
(factor analysis and clinical impact) are compared to
determine the effect of the method of item reduction on
the ﬁnal PTRQoL instrument.
OBJECTIVE: To perform a factor analysis of 57-items of
the developmental-version of the PTRQoL (d-PTRQoL)
and to determine if the results differ from a previous 
clinical impact method item reduction of the same 
57-items.
METHODS: Factor analysis (using principal axis factor-
ing and direct oblimin method of rotation with 125 iter-
ations) was performed on a dataset accumulated from a
previous work to compare results of the clinical impact
item reduction from a separate dataset. The dataset (n =
182) used was obtained earlier by a survey of patients
from various community pharmacies using the d-
PTRQoL (93-items on a six-point likert scale). Factor
analysis was restricted to the same 57 items used in the
